150 related articles for article (PubMed ID: 28346715)
1. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma.
Bulwer C; Conn R; Shankar A; Ferrau F; Kapur S; Ederies A; Korbonits M; Spoudeas HA
Clin Endocrinol (Oxf); 2017 Jun; 86(6):862-864. PubMed ID: 28346715
[No Abstract] [Full Text] [Related]
2. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.
Almanzar S; Zapata-Vega MI; Raya JA
Psychosomatics; 2013; 54(4):387-91. PubMed ID: 23261076
[No Abstract] [Full Text] [Related]
3. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.
Celik E; Ozkaya HM; Poyraz BC; Saglam T; Kadioglu P
Endocrine; 2018 Dec; 62(3):692-700. PubMed ID: 30206771
[TBL] [Abstract][Full Text] [Related]
4. A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With Prolactinoma.
Sahin S; Sudutan T; Kavla Y; Durcan E; Özogul YY; Poyraz BC; Sayitoglu M; Ozkaya HM; Kadioglu P
J Clin Endocrinol Metab; 2023 May; 108(6):e275-e282. PubMed ID: 36494095
[TBL] [Abstract][Full Text] [Related]
5. Treating prolactinomas with dopamine agonists: always worth the gamble?
Noronha S; Stokes V; Karavitaki N; Grossman A
Endocrine; 2016 Feb; 51(2):205-10. PubMed ID: 26336835
[TBL] [Abstract][Full Text] [Related]
6. Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review.
Hamblin R; Karavitaki N
Arch Med Res; 2023 Dec; 54(8):102910. PubMed ID: 37985276
[TBL] [Abstract][Full Text] [Related]
7. Atypical giant prolactinoma with frontal lobe manifestations.
Arshad MF; Arambewela M; Debono M
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30181411
[No Abstract] [Full Text] [Related]
8. Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications.
Lin S; Zhang A; Zhang X; Wu ZB
Neuroendocrinology; 2020; 110(6):477-488. PubMed ID: 31597135
[TBL] [Abstract][Full Text] [Related]
9. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
Oguz A; Tuzun D; Sahin M; Gul K
Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
[TBL] [Abstract][Full Text] [Related]
10. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
Almalki MH; Alsuraikh MA; Almalki E; Aziz F; Almazrouei R; AlDahmani KM; Alshahrani F; Alaqeel M; Mahzari M; Ekhzaimy A
Pituitary; 2024 Apr; 27(2):197-203. PubMed ID: 38345719
[TBL] [Abstract][Full Text] [Related]
11. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
12. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.
Dogansen SC; Cikrikcili U; Oruk G; Kutbay NO; Tanrikulu S; Hekimsoy Z; Hadzalic A; Gorar S; Omma T; Mert M; Akbaba G; Yalin GY; Bayram F; Ozkan M; Yarman S
J Clin Endocrinol Metab; 2019 Jul; 104(7):2527-2534. PubMed ID: 30848825
[TBL] [Abstract][Full Text] [Related]
13. Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.
Bettencourt-Silva R; Queirós J; Pereira J; Carvalho D
J Med Case Rep; 2018 Dec; 12(1):360. PubMed ID: 30518416
[TBL] [Abstract][Full Text] [Related]
14. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas.
Ozkaya HM; Sahin S; Korkmaz OP; Durcan E; Sahin HR; Celik E; Poyraz BC; Kadioglu P
Growth Horm IGF Res; 2020 Dec; 55():101356. PubMed ID: 33010581
[TBL] [Abstract][Full Text] [Related]
15. Nephrotic-range proteinuria in a patient with a giant prolactinoma.
Heras M; Iglesias P; Fernández-Reyes MJ; Sánchez R; Jiménez MJ; Muñoz H; Tajada P; Duarte J
Am J Kidney Dis; 2008 Jun; 51(6):1025-8. PubMed ID: 18455849
[TBL] [Abstract][Full Text] [Related]
16. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
Caputo C; Prior D; Inder WJ
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
[TBL] [Abstract][Full Text] [Related]
17. Prolactinoma presenting as painful postganglionic Horner syndrome.
Talkad AV; Kattah JC; Xu MY; Orth EH; Chang JY
Neurology; 2004 Apr; 62(8):1440-1. PubMed ID: 15111696
[No Abstract] [Full Text] [Related]
18. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
19. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Cackett P; Eunson G; Bath L; Mulvihill A
Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
[TBL] [Abstract][Full Text] [Related]
20. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
